Your session is about to expire
← Back to Search
Small Molecule
AZD1775 for Lung Cancer
Phase 2
Waitlist Available
Led By Jhanelle Gray, M.D.
Research Sponsored by H. Lee Moffitt Cancer Center and Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
Study Summary
This trial is testing a new cancer drug, to see if it is effective, and what side effects it may have.
Eligible Conditions
- Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Progression Free Survival (PFS)
Secondary outcome measures
Duration of Overall Response (OR)
Overall Survival (OS)
Percentage of Participants With Disease Control
Side effects data
From 2020 Phase 2 trial • 34 Patients • NCT0301247785%
Nausea
79%
Fatigue
74%
Vomiting
50%
Diarrhea
41%
Constipation
35%
Neutrophil count decreased
32%
Anemia
29%
Anorexia
26%
Pain
24%
Dysgeusia
24%
Headache
24%
Peripheral sensory neuropathy
21%
Dyspnea
21%
Tinnitus
18%
Cough
18%
Platelet count decreased
15%
Insomnia
15%
Urinary tract infection
12%
Back pain
12%
Dehydration
9%
Edema limbs
9%
Dizziness
9%
Gastrointestinal disorders - Other
9%
Hot flashes
9%
Lymphedema
9%
Abdominal pain
9%
Aspartate aminotransferase increased
9%
Creatinine increased
9%
Weight gain
6%
Confusion
6%
Dyspepsia
6%
Thromboembolic event
6%
Pruritus
6%
Rash acneiform
6%
Skin and subcutaneous tissue disorders - Other
6%
Alopecia
6%
Dry skin
6%
Weight loss
6%
Chest wall pain
6%
Myalgia
6%
Neck pain
3%
Alanine aminotransferase increased
3%
Alkaline phosphatase increased
3%
Pneumonitis
3%
Sepsis
3%
Breast pain
3%
Sinus pain
3%
Stomach pain
3%
Cognitive disturbance
3%
Anxiety
3%
Syncope
3%
Nervous system disorders - Other
3%
Pleural effusion
3%
Pain in extremity
3%
Depression
3%
Bruising
3%
Flatulence
3%
Rash maculo-papular
3%
Cardiac arrest
3%
Cardiac disorders - Other
3%
Sinus tachycardia
3%
Ear and labyrinth disorders - Other
3%
Arthralgia
3%
Palmar-plantar erythrodysesthesia syndrome
3%
Hearing impaired
3%
Endocrine disorders - Other
3%
Hypothyroidism
3%
Flu like symptoms
3%
Irritability
3%
Localized edema
3%
Non-cardiac chest pain
3%
Allergic reaction
3%
Cardiac troponin T increased
3%
Investigations - Other
3%
Acidosis
3%
Hypocalcemia
3%
Hypomagnesemia
3%
Hyponatremia
3%
Muscle weakness upper limb
3%
Chronic kidney disease
100%
80%
60%
40%
20%
0%
Study treatment Arm
Cisplatin + AZD1775
Trial Design
1Treatment groups
Experimental Treatment
Group I: Carboplatin/Paclitaxel/AZD1775Experimental Treatment3 Interventions
Treatment: Combination of AZD1775 plus carboplatin and paclitaxel. Participants will be treated with this combination of drugs twice daily on days 1 and 2 and once on day 3 for a total of 5 doses during each 21 day cycle of treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AZD1775
2015
Completed Phase 2
~400
Carboplatin
2014
Completed Phase 3
~6670
Paclitaxel
2011
Completed Phase 4
~5380
Find a Location
Who is running the clinical trial?
H. Lee Moffitt Cancer Center and Research InstituteLead Sponsor
542 Previous Clinical Trials
135,450 Total Patients Enrolled
Jhanelle Gray, M.D.Principal InvestigatorH. Lee Moffitt Cancer Center and Research Institute
6 Previous Clinical Trials
332 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have growing, symptomatic brain tumors that have not been treated yet.You can still participate if you have received chemotherapy after surgery.You have already received platinum or paclitaxel treatment for advanced lung cancer or are currently taking other approved or experimental anti-cancer drugs.You have a history of Torsades de pointes, a specific type of irregular heartbeat, unless all the things that caused it have been fixed.You have had another type of cancer in the past, but it was treated successfully and hasn't come back for at least 2 years.You have had a heart condition like unstable angina, a recent heart attack, severe heart failure, or abnormal heart rhythm that is not controlled by medication or a pacemaker.You are allowed to have received previous treatments such as immunotherapy or vaccines targeting certain proteins.
Research Study Groups:
This trial has the following groups:- Group 1: Carboplatin/Paclitaxel/AZD1775
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Has AZD1775 been tested in any other experiments of this type?
"In 1997, AZD1775 was initially experimented with at the City of Hope Comprehensive Cancer Center. As of now, there have been 1571 trials finished and 1187 are currently ongoing. Notably, a significant number of these studies are occurring out of Tampa, Florida."
Answered by AI
What is the total enrollment size of this research endeavor?
"At this point, individuals are not being recruited for this trial. It was initially posted on October 30th 2015 and the most recent update occured September 2nd 2022. If you're interested in alternate trials, there are 1628 studies recruiting participants with lung cancer and 1187 clinical trials looking to enrol patients that require AZD1775 treatment."
Answered by AI
Is enrollment for this trial currently available?
"Unfortunately, this clinical trial is no longer accepting new candidates. It was posted on October 30th 2015 and last modified September 2nd 2022. However, there are 1,628 active trials recruiting participants with lung cancer and another 1,187 seeking those eligible for AZD1775."
Answered by AI
Could you please elucidate the potential risks of taking AZD1775?
"Our team at Power evaluated AZD1775's safety and gave it a rating of 2, as the therapeutic has gone through Phase 2 testing but not yet demonstrated efficacy."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger